Inactive Instrument

Highlights Carbylan Therapeutics Inc Nasdaq

Equities

US1413841073

Highlights

Unlock all the news: Be the first to know and act before the market!

Sector Update: Health Care Stocks Higher Late Afternoon	05-31	MT
Sector Update: Health Care	05-31	MT
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise	05-31	MT
Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema	05-31	CI
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	03-18	CI
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	03-11	CI
KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	03-08	CI
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting	02-16	CI
KalVista meets main goals in late-stage trial for genetic disease	02-13	RE
KalVista meets main goals in late-stage trial for skin condition treatment	02-13	RE
Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema	02-13	CI
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	12-07	CI
Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved	11-13	CI
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology	11-02	CI
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-07	CI
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended April 30, 2023	23-07-06	CI
KalVista Pharmaceuticals, Inc. Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology	23-06-12	CI
KalVista Pharmaceuticals, Inc. Presents Data At 13Th C1-Inhibitor Deficiency & Angioedema Workshop	23-05-08	CI
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	23-03-09	CI
KalVista Pharmaceuticals, Inc. Provides Progress Updates on Sebetralstat Development	23-02-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Carbylan Therapeutics Inc Nasdaq

Equities

US1413841073

Highlights

Filters